Sterilization Method Selection for Injectable SVP/LVP
Regulatory preference: Terminal sterilization → SAL ≤10⁻⁶ → Aseptic only if justified
START: Define SVP/LVP Product
Volume: SVP ≤100mL or LVP >100mL
Bioburden: ≤10-100 CFU/100mL | SAL: ≤10⁻⁶
Endotoxin limits | FDA/EMA compliance
Bioburden: ≤10-100 CFU/100mL | SAL: ≤10⁻⁶
Endotoxin limits | FDA/EMA compliance
1 Evaluate Product Stability & Compatibility
Heat + Moisture Stable
Aqueous, stable at ≥121°C
(e.g., saline LVP, aqueous SVP)
→ MOIST HEAT
(Terminal – Preferred)
(Terminal – Preferred)
Steam: 121°C/15min
F₀ ≥8 min
Ideal for SVP & LVP
F₀ ≥8 min
Ideal for SVP & LVP
Heat Stable Only
Moisture-sensitive
(e.g., oily SVP suspensions)
→ DRY HEAT
(Terminal)
(Terminal)
≥160°C/2h
Depyrogenation
≥3-log endotoxin reduction
Depyrogenation
≥3-log endotoxin reduction
Heat Sensitive
Degrades at high temp
(e.g., biologic SVP, proteins)
→ STEP 2
(Alternative Methods)
(Alternative Methods)
2 Alternative Terminal or Aseptic Methods
Radiation Tolerant
No radiolysis issues
(e.g., pre-filled SVP syringes)
RADIATION
(Terminal)
(Terminal)
Surface Sterilization
Containers/closures
(rare for filled products)
CHEMICAL GAS
(EtO/VHP)
(EtO/VHP)
No Terminal Feasible
Heat-labile aqueous
(e.g., unstable APIs, biologics)
STERILE FILTRATION
+ ASEPTIC
+ ASEPTIC
END: Sterile Injectable SVP/LVP Achieved
cGMP compliance | Parametric release if validated
Continuous monitoring & periodic revalidation
Continuous monitoring & periodic revalidation
Key Points:
• SVP: Small Volume Parenterals (≤100mL)
• LVP: Large Volume Parenterals (>100mL)
• SAL: Sterility Assurance Level ≤10⁻⁶
• F₀: Equivalent exposure time at 121°C
• CFU: Colony Forming Units
• EU: Endotoxin Units
